BR112019028046A2 - métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos - Google Patents

métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos Download PDF

Info

Publication number
BR112019028046A2
BR112019028046A2 BR112019028046-4A BR112019028046A BR112019028046A2 BR 112019028046 A2 BR112019028046 A2 BR 112019028046A2 BR 112019028046 A BR112019028046 A BR 112019028046A BR 112019028046 A2 BR112019028046 A2 BR 112019028046A2
Authority
BR
Brazil
Prior art keywords
subject
dose
asc
initial
fact
Prior art date
Application number
BR112019028046-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Narimon Honarpour
Malik Fady
Original Assignee
Amgen Inc.
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc., Cytokinetics, Inc. filed Critical Amgen Inc.
Publication of BR112019028046A2 publication Critical patent/BR112019028046A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112019028046-4A 2017-06-30 2018-06-29 métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos BR112019028046A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
US62/527,983 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Publications (1)

Publication Number Publication Date
BR112019028046A2 true BR112019028046A2 (pt) 2020-07-07

Family

ID=63013097

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019028046-4A BR112019028046A2 (pt) 2017-06-30 2018-06-29 métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos

Country Status (22)

Country Link
US (4) US11576910B2 (https=)
EP (2) EP3645002B1 (https=)
JP (3) JP2020526483A (https=)
CN (1) CN110996953A (https=)
AU (2) AU2018290983B2 (https=)
BR (1) BR112019028046A2 (https=)
CA (1) CA3068588A1 (https=)
DK (1) DK3645002T3 (https=)
ES (1) ES3008457T3 (https=)
FI (1) FI3645002T3 (https=)
HR (1) HRP20241729T1 (https=)
HU (1) HUE069805T2 (https=)
LT (1) LT3645002T (https=)
MA (1) MA49508B1 (https=)
MD (1) MD3645002T2 (https=)
MX (2) MX2020000190A (https=)
PL (1) PL3645002T3 (https=)
PT (1) PT3645002T (https=)
RS (1) RS66581B1 (https=)
SI (1) SI3645002T1 (https=)
SM (1) SMT202500067T1 (https=)
WO (1) WO2019006235A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
DK3645002T3 (da) * 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
KR20220009440A (ko) * 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료
US20230090391A1 (en) * 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
WO2021257456A1 (en) * 2020-06-15 2021-12-23 MyoKardia, Inc. Treatment of atrial dysfunction
DK4243825T3 (da) * 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス， インコーポレイテッド １，４－ジヒドロキナゾリノン化合物およびその使用
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
AU2003279842A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US20080031957A1 (en) 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
US9895308B2 (en) * 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
CA3052625A1 (en) 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
DK3645002T3 (da) 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
EP3820851A1 (en) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
FI3599243T3 (fi) 2018-07-26 2023-06-22 Cvie Therapeutics Ltd 17beeta-heterosyklyylidigitaliksen kaltaisia yhdisteitä sydämen vajaatoiminnan hoitoon
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
MX2021010483A (es) 2019-03-05 2021-10-01 Windtree Therapeutics Inc Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf).
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
EP4054588A4 (en) 2019-11-10 2023-12-13 MyoKardia, Inc. Methods of treatment with myosin modulator
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
US20230090391A1 (en) 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
EP4512470A3 (en) 2025-04-23
US11576910B2 (en) 2023-02-14
HUE069805T2 (hu) 2025-04-28
MX2020000190A (es) 2020-07-22
EP3645002A1 (en) 2020-05-06
SMT202500067T1 (it) 2025-03-12
CA3068588A1 (en) 2019-01-03
EP3645002B1 (en) 2024-10-30
US20250255862A1 (en) 2025-08-14
US20200155547A1 (en) 2020-05-21
AU2024200991B2 (en) 2025-04-10
AU2024200991A1 (en) 2024-03-07
US11931358B2 (en) 2024-03-19
AU2018290983A1 (en) 2020-01-23
RS66581B1 (sr) 2025-04-30
MA49508A (fr) 2020-05-06
PT3645002T (pt) 2025-01-24
AU2018290983B2 (en) 2023-11-23
WO2019006235A1 (en) 2019-01-03
MA49508B1 (fr) 2024-12-31
HRP20241729T1 (hr) 2025-03-14
MX2022015115A (es) 2023-01-18
PL3645002T3 (pl) 2025-03-24
JP2025165979A (ja) 2025-11-05
FI3645002T3 (fi) 2025-01-29
JP2020526483A (ja) 2020-08-31
MD3645002T2 (ro) 2025-04-30
DK3645002T3 (da) 2024-12-16
ES3008457T3 (en) 2025-03-24
CN110996953A (zh) 2020-04-10
US12295952B2 (en) 2025-05-13
EP4512470A2 (en) 2025-02-26
LT3645002T (lt) 2025-02-10
SI3645002T1 (sl) 2025-03-31
JP2023088944A (ja) 2023-06-27
US20230149394A1 (en) 2023-05-18
US20230355615A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
US11931358B2 (en) Methods of treating heart failure with cardiac sarcomere activators
Sayin et al. Left ventricular hypertrophy: etiology-based therapeutic options
Gorter et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology
US20220313695A1 (en) Treatment of hcm with pyrimidinedione compounds
Upadhya et al. Heart failure with preserved ejection fraction in older adults
Cohn Current therapy of the failing heart.
JP2024500616A (ja) オメカムチブメカルビルの投与により心不全を処置する方法
ES3014965T3 (en) Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
KR20250050043A (ko) 비폐쇄성 비대심근병증 치료 방법
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
Woodland et al. New Era: Mavacamten for obstructive hypertrophic cardiomyopathy
KR20250056200A (ko) 폐쇄성 비대심장근육병증 치료 방법
US20200306222A1 (en) Dosing Regimen of Siponimod
Aronow Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons
Sinner et al. Response to cardiac resynchronization therapy in non‐ischemic cardiomyopathy is unrelated to medical therapy
HK40028258A (en) Methods of treating heart failure with cardiac sarcomere activators
HK40028258B (en) Methods of treating heart failure with cardiac sarcomere activators
HK40027649A (en) Methods of treating heart failure with cardiac sarcomere activators
Buitenwerf et al. Efficacy of phenoxybenzamine versus doxazosin on hemodynamic control during pheochromocytoma resection-a randomized controlled trial. Supplemental data. Figshare repository
Finimundi et al. Effect of diuretic therapy on exercise capacity in patients with chronic angina and preserved left ventricular function
Hamze et al. Sodium-glucose cotransporter 2 inhibition restores testicular microvascular perfusion via endothelial signaling in a large animal model of metabolic syndrome and heart failure
Oto Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
Johnson Management of patients with left ventricular hypertrophy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]